Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial

被引：0
|
作者：
Todd J. Schwedt
Tina M. Myers Oakes
James M. Martinez
Bert B. Vargas
Hitendra Pandey
Eric M. Pearlman
Diane R. Richardson
Oralee J. Varnado
Michael Cobas Meyer
Peter J. Goadsby
机构：
[1] Mayo Clinic,NIHR King’s Clinical Research Facility and Headache Group, Institute of Psychiatry, Psychology and Neuroscience
[2] Eli Lilly and Company,Department of Neurology
[3] King’s College London,undefined
[4] University of California,undefined
来源：
Neurology and Therapy | 2024年 / 13卷
关键词：
Calcitonin gene-related peptide (CGRP); CGRP antagonist; Galcanezumab; Gepant; Head-to-head; Migraine; Prevention; Rimegepant; Clinical study; Comparative efficacy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Galcanezumab and rimegepant are preventive treatments for episodic migraine. The goal of this study was to compare the efficacy of galcanezumab and rimegepant in reducing the number of monthly migraine headaches and to determine if galcanezumab was better than rimegepant. The study provides important information to doctors and their patients when making treatment decisions.
引用
收藏
页码：85 / 105
页数：20
相关论文
共 50 条
  • [1] Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial
    Schwedt, Todd J.
    Oakes, Tina M. Myers
    Martinez, James M.
    Vargas, Bert B.
    Pandey, Hitendra
    Pearlman, Eric M.
    Richardson, Diane R.
    Varnado, Oralee J.
    Meyer, Michael Cobas
    Goadsby, Peter J.
    NEUROLOGY AND THERAPY, 2024, 13 (01) : 85 - 105
  • [2] Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
    Skljarevski, Vladimir
    Matharu, Manjit
    Millen, Brian A.
    Ossipov, Michael H.
    Kim, Byung-Kun
    Yang, Jyun Yan
    CEPHALALGIA, 2018, 38 (08) : 1442 - 1454
  • [3] Challenge-mig: a phase 4, randomized, double-blind, double-dummy study comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine
    Schwedt, Todd J.
    Oakes, Tina M. Myers
    Martinez, James M.
    Vargas, Bert B.
    Pandey, Hitendra N.
    Pearlman, Eric M.
    Richardson, Diane R.
    Varnado, Oralee J.
    Meyer, Michael Cobas
    Goadsby, Peter J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [4] Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial
    Stauffer, Virginia L.
    Dodick, David W.
    Zhang, Qi
    Carter, Jeffrey N.
    Ailani, Jessica
    Conley, Robert R.
    JAMA NEUROLOGY, 2018, 75 (09) : 1080 - 1088
  • [5] Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention A Randomized Clinical Trial
    Skljarevski, Vladimir
    Oakes, Tina M.
    Zhang, Qi
    Ferguson, Margaret B.
    Martinez, James
    Camporeale, Angelo
    Johnson, Kirk W.
    Shan, Qiuling
    Carter, Jeffrey
    Schacht, Aaron
    Goadsby, Peter J.
    Dodick, David W.
    JAMA NEUROLOGY, 2018, 75 (02) : 187 - 193
  • [6] HEALTHCARE UTILIZATION AND COSTS AMONG PATIENTS WITH EPISODIC MIGRAINE INITIATING GALCANEZUMAB VERSUS RIMEGEPANT FOR MIGRAINE PREVENTION IN THE UNITED STATES
    Kim, G.
    Hoyt, M.
    Durica, J.
    Zakharyan, A.
    Wallem, A.
    Viktrup, L.
    VALUE IN HEALTH, 2024, 27 (06) : S391 - S391
  • [7] Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials
    Gao, Bixi
    Yang, Yanbo
    Wang, Zilan
    Sun, Yue
    Chen, Zhouqing
    Zhu, Yun
    Wang, Zhong
    FRONTIERS IN PHARMACOLOGY, 2020, 10
  • [8] Atorvastatin versus Propranolol in Prevention of Episodic Migraine. A Randomized Clinical Trial
    Marfil-Rivera, Alejandro
    Flores, Hazael
    NEUROLOGY, 2016, 86
  • [9] Safety from Phase 3 Clinical Studies Comparing Galcanezumab and Placebo in Patients Episodic and Chronic Migraine
    Bangs, Mark E.
    Kudrow, David
    Wang, Shufang
    Oakes, Tina M.
    Carter, Jeffrey N.
    Terwindt, Gisela M.
    Magis, Delphine
    Stauffer, Virginia L.
    NEUROLOGY, 2019, 92 (15)
  • [10] Clinical efficacy and safety of rimegepant in the treatment of migraine: a meta-analysis of randomized controlled trials
    Wang, Qinghui
    Wang, Shuangmei
    Zhu, Yi
    Lin, Fei
    FRONTIERS IN NEUROLOGY, 2023, 14
12345